The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL)

被引:40
|
作者
Bavi, Prashant [1 ]
Uddin, Shahab [1 ]
Bu, Rong [1 ]
Ahmed, Maqbool [1 ]
Abubaker, Jehad [1 ]
Balde, Valorie [1 ]
Qadri, Zeeshan [1 ]
Ajarim, Dahish [2 ]
Al-Dayel, Fouad [3 ]
Hussain, Azhar R. [1 ]
Al-Kuraya, Khawla S. [1 ]
机构
[1] King Faisal Specialist Hosp & Res Canc, Res Ctr, King Fahad Natl Ctr Childrens Canc, Riyadh 11211, Saudi Arabia
[2] King Faisal Canc Ctr, Riyadh, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Canc, Dept Pathol, Riyadh 11211, Saudi Arabia
来源
JOURNAL OF PATHOLOGY | 2011年 / 224卷 / 03期
关键词
DLBCL; NF-kappa B; NHL therapy; activated B cell (ABC) phenotype; apoptosis; XIAP; tissue microarray; TISSUE MICROARRAY ANALYSIS; PRIMARY EFFUSION LYMPHOMA; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; CANCER-THERAPY; SAUDI-ARABIA; PATHWAY; KINASE; ALPHA;
D O I
10.1002/path.2864
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
NF-kappa B is frequently over-expressed in a variety of non-Hodgkin's lymphomas (NHLs) and has been implicated in lymphomagenesis; however, its role in diffuse large B cell lymphoma (DLBCL) as a prognostic biomarker has not been fully elucidated. Therefore, we investigated the role of NF-kappa B and its association with clinicopathological features in a tissue microarray cohort of 230 DLBCL patient samples. We then elucidated the role of NF-kappa B inhibition on cell viability and apoptosis in vitro, using DLBCL cell lines. Using immunohistochemistry, NF-kappa B was detected in 25.6% (52/203) DLBCL tumours, was associated with activated B cell (ABC) phenotype (p = 0.0054), Epstein-Barr virus (EBV; p = 0.0080) and over-expression of the anti-apoptotic marker XIAP (p = 0.0013). DLBCL cases with nuclear expression of NF-kappa B showed a significantly poorer overall survival as compared to those without NF-kappa B expression (p = 0.0236). In a multivariate analysis using a Cox proportional hazard model for IPI and NF-kappa B expression, the relative risk was 2.97 for high NF-kappa B expression (95% CI 1.27-6.94; p = 0.0113) and 7.55 for the high-IPI group (95% CI 3.34-18.35; p < 0.0001). In vitro, Bay 11-7085 inhibited constitutively active NF-kappa B expression in a dose-dependent manner and inhibition of NF-kappa B also down-regulated expression of the downstream target gene products Bcl-2, Bcl-XL (BCL2L1), XIAP and Survivin, leading to apoptosis via activation of the mitochondrial apoptotic pathway. NF-kappa B over-expression was found to be an independent prognostic marker for poor survival in DLBCL. Altogether, these results suggest that NF-kappa B may be a useful prognostic biomarker and a potential target for therapeutic intervention in DLBCL. Copyright (C) 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:355 / 366
页数:12
相关论文
共 50 条
  • [41] Examining genetic ancestry in diffuse large B-cell lymphoma (DLBCL)
    Lee, Michelle J.
    Jhaney, Camber Ileen
    Flowers, Christopher R.
    Koff, Jean L.
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Management of DLBCL (Diffuse Large B-Cell Lymphoma): A Monocentric Experience
    Tlohi, Kawtar
    Benmoussa, Amine
    Harrach, Asmaa
    Lamchahab, Mouna
    Rachid, Mohamed
    Khoubila, Nissrine
    Cherkaoui, Siham
    Qachouh, Meryem
    Mandani, Abdellah
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S431 - S431
  • [43] Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)
    Isshiki, Yusuke
    Melnick, Ari
    CURRENT CANCER DRUG TARGETS, 2021, 21 (04) : 274 - 282
  • [44] Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalac, Matko
    Mangone, Michael
    Rinderspacher, Alison
    Deng, Shi-Xian
    Scotto, Luigi
    Vendome, Jeremie
    Bansal, Mukesh
    Califano, Andrea
    Landry, Donald
    O'Connor, Owen A.
    BLOOD, 2015, 126 (23)
  • [45] CLINICAL FEATURES AND SURVIVAL OF PATIENTS WITH LATE RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Castillo-Giron, C.
    Rivas-Delgado, A.
    Dlouhy, I
    Rovira, J.
    Mozas, P.
    Rivero, A.
    Frigola, G.
    Balague, O.
    Baumann, T.
    Correa, J. G.
    Magnano, L.
    Jimenez-Vicente, C.
    Gomez, M.
    Delgado, J.
    Villamor, N.
    Campo, E.
    Gine, E.
    Lopez-Guillermo, A.
    HAEMATOLOGICA, 2020, 105 : 291 - 292
  • [46] Clinical approach to diffuse large B cell lymphoma
    Caimi, Paolo F.
    Hill, Brian T.
    Hsi, Eric D.
    Smith, Mitchell R.
    BLOOD REVIEWS, 2016, 30 (06) : 477 - 491
  • [47] Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma
    Go, Se-Il
    Park, Sungwoo
    Kang, Myoung Hee
    Kim, Hoon-Gu
    Kim, Hye Ree
    Lee, Gyeong-Won
    ANNALS OF HEMATOLOGY, 2019, 98 (02) : 401 - 411
  • [48] Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma
    Se-Il Go
    Sungwoo Park
    Myoung Hee Kang
    Hoon-Gu Kim
    Hye Ree Kim
    Gyeong-Won Lee
    Annals of Hematology, 2019, 98 : 401 - 411
  • [49] CLINICAL IMPACT OF KARYOTYPIC EVOLUTION ON THE PROGNOSIS OF DIFFUSE LARGE B CELL LYMPHOMA
    Mizuno, Y.
    Kobayashi, T.
    Uoshima, N.
    Kawata, E.
    Uchiyama, H.
    Chinen, Y.
    Shimura, Y.
    Horiike, S.
    Kuroda, J.
    HAEMATOLOGICA, 2017, 102 : 394 - 395
  • [50] NF-κB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines
    Meli, M
    D'Alessandro, N
    Tolomeo, M
    Rausa, L
    Notarbartolo, M
    Dusonchet, L
    APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS, 2003, 1010 : 232 - 236